生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Tandem Mobi Improves Quality of Life for People Living With
Type 1 Diabetes
in New Data Shared at American
Diabetes
Association Scientific Sessions
2024-06-22
·
BioSpace
SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and
diabetes
technology company, today presented new real-world insights from a survey on Tandem Mobi user satisfaction and wearability during the 84th Scientific Sessions of the American Diabetes Association (ADA) taking place in Orlando, Florida. The survey found that 86 percent of participants were satisfied or very satisfied with Tandem Mobi regardless of prior therapy and agreed that Tandem Mobi helps improve their quality of life.1 Tandem Mobi, the world’s smallest, durable automated insulin delivery (AID) system, became commercially available in the United States in February of 2024. “These real-world user insights provide evidence that we are furthering our mission to improve the lives of people with
diabetes
by demonstrating that Tandem Mobi not only meets, but exceeds user expectations,” said Jordan Pinsker, MD, chief medical officer at
Tandem Diabetes Care
Diabetes
Care. “We are proud to share these results at ADA and will continue to innovate to provide the
diabetes
community with choice and improved quality of life.” In the six-week limited launch survey, early users who were previously using multiple daily injections (MDI), other insulin pumps (tubed and tubeless), or were previous
Tandem
pump users, also exhibited high satisfaction with the unique wearability features of Tandem Mobi combined with the Control-IQ algorithm. Tandem Mobi is so small that it can be worn almost anywhere2, giving users greater discretion, comfort, and flexibility. Meanwhile, Control-IQ technology predicts and helps prevent highs and lows.3 Of prior MDI users: 84 percent say Tandem Mobi reduces the burden of managing their
diabetes
82 percent say Tandem Mobi is easy to use 77 percent say Tandem Mobi helps them feel they have more freedom in their lives Of prior pump users: 78 percent say Tandem Mobi reduces the burden of managing their
diabetes
88 percent say Tandem Mobi is easy to use 80 percent say Tandem Mobi helps them feel they have more freedom in their lives Barbara Davis Center Study of Early Users Also shared at ADA were insights from an independent study involving Tandem Mobi users. The results showed that time in range improved with no increase in time spent below range. For younger participants, form factor, portability, discreteness, and wearability are paramount to satisfaction and ongoing use. Tandem Mobi offers many options that support the needs of youth with
type 1 diabetes
, including: Minimum fill (30 units) - Less insulin waste for users with low
insulin
requirements Physical on-pump Quick Bolus button - Simple, discreet bolusing with programming in grams or unit increments On-body wear with a lightweight adhesive sleeve and 5-inch tubing (each sold separately) Personal, compatible iPhone control The product theater was recorded and will be available on the ADA website following the close of the conference for access by registered attendees, and on the
Tandem
website at tandemdiabetes.com/providers/events. 1 As of June 2024. Data on file,
Tandem Diabetes Care
Diabetes
Care. 2 The pump should not be placed more than 12 inches (30.5 cm) above the infusion site. Doing so may result in over delivery of
insulin
. 3 All published clinical trials and real-world studies of Control-IQ technology to date are based on use of Dexcom G6 CGM with the
Tandem
t:slim X2 insulin pump. About
Tandem Diabetes Care
Diabetes
Care
Tandem Diabetes Care
Diabetes
Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of
diabetes
management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology.
Tandem Diabetes Care
Diabetes
Care is based in San Diego, California. For more information, visit tandemdiabetes.com. Follow
Tandem Diabetes Care
Diabetes
Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and #TandemDiabetes. Follow
Tandem Diabetes Care
Diabetes
Care on Facebook at . Follow
Tandem Diabetes Care
Diabetes
Care on LinkedIn at . © 2024
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. All rights reserved.
Tandem Diabetes Care
Diabetes
Care,
Tandem
logos, Control-IQ, t:slim X2, and Tandem Mobi are trademarks of
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners. Responsible Use of Control-IQ technology Control-IQ technology does not prevent all highs and lows. Users must still bolus for meals and actively manage their
diabetes
. Visit tandemdiabetes.com/responsible-use for additional important safety information. Important Safety Information
RX ONLY
. Indications for Use: Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of
insulin
, at set and variable rates, for the management of
diabetes mellitus
in persons requiring
insulin
. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 6 years of age and greater. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is intended for the subcutaneous delivery of
insulin
, at set and variable rates, for the management of
diabetes mellitus
in people requiring
insulin
. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient use. The pump is indicated for use with NovoLog or Humalog U-100 insulin. The pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of
Type 1 diabetes mellitus
in persons 6 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin. WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of
insulin
per day or who weigh less than 55 pounds. Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using
hydroxyurea
. Users of a
Tandem
insulin pump and Control-IQ technology must use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient
diabetes
self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The
Tandem
pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information. View source version on businesswire.com: Contacts Source:
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. View this news release online at:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务